by: TN Media News
Dr. Saeed Al-Amoudi, Genalive Medical Chief Executive Officer “The laboratories will contribute to the detecting and reducing the spread of hereditary diseases, and the nationalization of genetic testing”
“Genalive Medical Laboratories” is a Strategic Partnership between Arabian International Healthcare Holding Company and BGI AlManahil
Riyadh / Thursday, 18 Dhu Al-Qa’dah 1444H, (08 June 2023G): His Excellency the Deputy Minister of Health, Engineer Abdulaziz bin Hamad Al Rumaih, inaugurated yesterday Genalive Medical Laboratories in the presence of the members of the Board of Directors of Arabian International Healthcare Holding Company and its Chief Executive Officer, BGI Group Chief Executive Officer, and several health leaders in the Kingdom.
Founded on an area of more than 4000 square meters, Genalive Medical laboratories is the largest state of the art laboratory specialized center in the Kingdom that provides comprehensive solutions to its patients, utilizing the most advanced diagnostic techniques.
The laboratories aim to nationalize specialized genetic testing and offer routine examinations, including blood, biochemical, immune, and genetic examinations spanning genetic diseases, genetic venereal, genetic cancerous diseases as well as diagnostic medicine examinations for cancerous diseases.
Commenting on the inauguration, Dr. Saeed Al-Amoudi, CEO of Genalive Medical said “I would like to express my happiness on the opening of Genalive Medical laboratories, the first of its kind in the Kingdom and is distinguished by the establishment of the largest private biodata center.
We will be able to analyse data and detect genetic variants quickly and accurately while respecting and adhering to the full privacy policy for the data of all of our patients and visitors.”
He clarified that these examinations are a key pillar in reducing the spread of genetic diseases. It gives individuals the opportunity to carry out early testing before marriage, before, during and after pregnancy as well as before embryo transfer.
He pointed out that in addition to genetic diseases examinations, Genalive will offer hereditary consultations that enable individuals to take informed decisions in all matters that are related to their health and the health of their families and relatives, resulting in improving the health of the society and the quality of life.
Al Amoudi added that the company will directly contribute to the provision of a number of new benefits that have not been previously available to serve the health sector in the Kingdom, such as the nationalization of genetic tests.
This in turn will help reduce spending on laboratory services, reduce sending laboratory samples abroad, further enhancing the competencies of the Saudi cadres, and transferring advanced technologies from BGI Group to the Kingdom.
Specialized genetic testing infrastructure will be enhanced, contributing to the prevention of hereditary diseases and the provision of a database for the Saudi society, which will boost the efficiency and accuracy of disease diagnosis as well as enhancing huge data and artificial intelligence capabilities.
Genalive Laboratories is ambitious at a large scale to support the research, development and innovation system and achieve the goals of the health sector transformation program.
Genetics and biotechnology are particularly important to medical and scientific authorities in the Kingdom and Genalive Medical has been driven to establish research partnerships with different institutions to offer comprehensive solutions and the most advanced technology, not to mention supporting biodata and scientific research.
In addition, Genalive CEO stressed that the company is ambitious to support the achievement of the Kingdom’s Vision 2030 goals and to represent a global model in the general and specialized laboratory services that use the various types of Omics techniques, one of the most important techniques that are used for prevention of diseases.
These techniques enable us to study the genetic composition and measure and classify the various biological molecules in order to assess the human condition in healthy and unhealthy situations. Omics techniques also contribute to the prevention, diagnosis, and treatment of diseases, as well as enabling the diagnostic medicine.
Finally, Dr. Al Amoudi unveiled that Genalive Medical has been established as a strategic partnership between BGI Group, a leader in life science technologies, and Arabian International Healthcare Holding Company, that has long-standing experience in providing comprehensive health care solutions in the Kingdom.
The health transformation program constitutes one of the Kingdom’s Vision 2030 key pillars that seeks to restructure the health sector to best serve both the individual and the society and ensure maximum level of attention to general health.
The program also promotes prevention of diseases, facilitates individuals’ access to health care services, and improves both its efficiency and quality.
